DESCRIPTION: The American Society of Addiction Medicine (ASAM) has partnered with nine other medical societies and professional associations representing a wide range of clinical settings and patient populations to provide guidance on evidence-based strategies for tapering benzodiazepine (BZD) medication across a variety of settings. METHODS: The guideline was developed following modifed GRADE methodology and clinical consensus process. The process included a systematic literature review as well as several targeted supplemental searches. The clinical practice guideline was revised based on external stakeholder review. RECOMMENDATIONS: Key takeaways included the following: Clinicians should engage in ongoing risk–beneft assessment of BZD use/tapering, clinicians should utilize shared decision-making strategies in collaboration with patients, clinicians should not discontinue BZDs abruptly in patients who are likely to be physically dependent and at risk of withdrawal, clinicians should tailor tapering strategies to each patient and adjust tapering based on patient response, and clinicians should offer patients adjunctive psychosocial interventions to support successful tapering.

描述：美国成瘾医学学会（ASAM）已与代表广泛临床场景和患者群体的其他九个医学学会及专业协会合作，针对各种场景下苯二氮卓类药物（BZD）减量的循证策略提供指导。方法：本指南采用改良GRADE方法学和临床共识流程制定，包括系统文献综述及多项针对性补充检索，并基于外部利益相关者的反馈进行修订。推荐意见：核心要点如下：临床医生应对苯二氮卓类药物使用/减量进行持续风险获益评估；应采用与患者共同决策的策略；对可能存在生理依赖及戒断风险的患者，不应突然停用苯二氮卓类药物；减量策略需个体化，并根据患者反应调整；应为患者提供辅助心理社会干预措施以支持成功减量。